FY2027 EPS Estimates for Novavax Decreased by Zacks Research

Novavax, Inc. (NASDAQ:NVAX - Free Report) - Research analysts at Zacks Research lowered their FY2027 earnings estimates for shares of Novavax in a report released on Monday, April 14th. Zacks Research analyst S. Ganoria now forecasts that the biopharmaceutical company will post earnings per share of $0.51 for the year, down from their prior estimate of $0.54. The consensus estimate for Novavax's current full-year earnings is ($1.46) per share.

A number of other equities analysts have also recently weighed in on NVAX. TD Cowen raised Novavax to a "hold" rating in a research note on Thursday, February 27th. BTIG Research began coverage on shares of Novavax in a research note on Friday, February 28th. They set a "buy" rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Novavax currently has an average rating of "Hold" and a consensus target price of $18.00.

Novavax Stock Performance

Shares of NVAX stock traded up $0.16 during mid-day trading on Wednesday, hitting $6.16. 1,501,975 shares of the stock traded hands, compared to its average volume of 8,235,189. Novavax has a twelve month low of $3.90 and a twelve month high of $23.86. The company's 50-day simple moving average is $7.27 and its 200-day simple moving average is $8.54. The firm has a market cap of $990.80 million, a price-to-earnings ratio of -2.73, a price-to-earnings-growth ratio of 2.85 and a beta of 3.15.

Novavax (NASDAQ:NVAX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same quarter last year, the firm posted ($1.44) EPS.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Novavax by 26.7% in the 3rd quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock valued at $97,099,000 after purchasing an additional 1,621,772 shares during the last quarter. Wellington Management Group LLP acquired a new position in shares of Novavax in the 3rd quarter valued at $923,000. Barclays PLC grew its stake in shares of Novavax by 73.9% during the third quarter. Barclays PLC now owns 709,579 shares of the biopharmaceutical company's stock worth $8,961,000 after purchasing an additional 301,627 shares during the period. Geode Capital Management LLC lifted its stake in Novavax by 9.5% in the third quarter. Geode Capital Management LLC now owns 3,502,489 shares of the biopharmaceutical company's stock valued at $44,245,000 after buying an additional 304,159 shares during the period. Finally, Franklin Resources Inc. grew its position in shares of Novavax by 300.4% during the 3rd quarter. Franklin Resources Inc. now owns 97,162 shares of the biopharmaceutical company's stock worth $1,226,000 after buying an additional 72,894 shares during the period. 53.04% of the stock is currently owned by institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.